Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018
Published by Elsevier Ltd..
BACKGROUND: Estimating the burden of disease averted by vaccination can assist policymakers to implement, adjust, and communicate the value of vaccination programs. Demonstrating the use of a newly available modeling tool, we estimated the burden of influenza illnesses averted by seasonal influenza vaccination in El Salvador, Panama, and Peru during 2011-2017 among two influenza vaccine target populations: children aged 6-23 months and pregnant women.
METHODS: We derived model inputs, including incidence, vaccine coverage, vaccine effectiveness, and multipliers from publicly available country-level influenza surveillance data and cohort studies. We also estimated changes in illnesses averted when countries' vaccine coverage was achieved using four different vaccine deployment strategies.
RESULTS: Among children aged 6-23 months, influenza vaccination averted an estimated cumulative 2,161 hospitalizations, 81,907 medically-attended illnesses, and 126,987 overall illnesses during the study period, with a prevented fraction ranging from 0.3 % to 12.5 %. Among pregnant women, influenza vaccination averted an estimated cumulative 173 hospitalizations, 6,122 medically attended illnesses, and 16,412 overall illnesses, with a prevented fraction ranging from 0.2 % to 10.9 %. Compared to an influenza vaccine campaign with equal vaccine distribution during March-June, scenarios in which total cumulative coverage was achieved in March and April consistently resulted in the greatest increase in averted illness (23 %-3,129 % increase among young children and 22 %-3,260 % increase among pregnant women).
DISCUSSION: Influenza vaccination campaigns in El Salvador, Panama, and Peru conducted between 2011 and 2018 prevented hundreds to thousands of influenza-associated hospitalizations and illnesses in young children and pregnant women. Existing vaccination programs could prevent additional illnesses, using the same number of vaccines, by achieving the highest possible coverage within the first two months of an influenza vaccine campaign.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Vaccine - (2024) vom: 06. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chard, Anna N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Averted illness |
|---|
| Anmerkungen: |
Date Revised 07.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.vaccine.2024.04.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370734688 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370734688 | ||
| 003 | DE-627 | ||
| 005 | 20240408233355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.04.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370734688 | ||
| 035 | |a (NLM)38584055 | ||
| 035 | |a (PII)S0264-410X(24)00419-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chard, Anna N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Estimating the burden of disease averted by vaccination can assist policymakers to implement, adjust, and communicate the value of vaccination programs. Demonstrating the use of a newly available modeling tool, we estimated the burden of influenza illnesses averted by seasonal influenza vaccination in El Salvador, Panama, and Peru during 2011-2017 among two influenza vaccine target populations: children aged 6-23 months and pregnant women | ||
| 520 | |a METHODS: We derived model inputs, including incidence, vaccine coverage, vaccine effectiveness, and multipliers from publicly available country-level influenza surveillance data and cohort studies. We also estimated changes in illnesses averted when countries' vaccine coverage was achieved using four different vaccine deployment strategies | ||
| 520 | |a RESULTS: Among children aged 6-23 months, influenza vaccination averted an estimated cumulative 2,161 hospitalizations, 81,907 medically-attended illnesses, and 126,987 overall illnesses during the study period, with a prevented fraction ranging from 0.3 % to 12.5 %. Among pregnant women, influenza vaccination averted an estimated cumulative 173 hospitalizations, 6,122 medically attended illnesses, and 16,412 overall illnesses, with a prevented fraction ranging from 0.2 % to 10.9 %. Compared to an influenza vaccine campaign with equal vaccine distribution during March-June, scenarios in which total cumulative coverage was achieved in March and April consistently resulted in the greatest increase in averted illness (23 %-3,129 % increase among young children and 22 %-3,260 % increase among pregnant women) | ||
| 520 | |a DISCUSSION: Influenza vaccination campaigns in El Salvador, Panama, and Peru conducted between 2011 and 2018 prevented hundreds to thousands of influenza-associated hospitalizations and illnesses in young children and pregnant women. Existing vaccination programs could prevent additional illnesses, using the same number of vaccines, by achieving the highest possible coverage within the first two months of an influenza vaccine campaign | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Averted illness | |
| 650 | 4 | |a Compartment model | |
| 650 | 4 | |a Influenza epidemiology | |
| 650 | 4 | |a Influenza vaccine | |
| 650 | 4 | |a Vaccine effectiveness | |
| 700 | 1 | |a Machingaidze, Chiedza |e verfasserin |4 aut | |
| 700 | 1 | |a Loayza, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Gharpure, Radhika |e verfasserin |4 aut | |
| 700 | 1 | |a Nogareda, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a González, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez, Rhina |e verfasserin |4 aut | |
| 700 | 1 | |a Tinoco, Yeny O |e verfasserin |4 aut | |
| 700 | 1 | |a Dawood, Fatimah S |e verfasserin |4 aut | |
| 700 | 1 | |a Carreon, Joseph Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Lafond, Kathryn E |e verfasserin |4 aut | |
| 700 | 1 | |a Jara, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Azziz-Baumgartner, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Cozza, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Couto, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Rolfes, Melissa A |e verfasserin |4 aut | |
| 700 | 1 | |a Tempia, Stefano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g (2024) vom: 06. Apr. |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2024.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 04 | ||